Project Details
Description
A Phase 2b, Double-Blind, Active Comparator-Controlled Study to Assess the Efficacy, Immunogenicity, and Safety of GRT-R924 as a Next-Generation COVID-19 Booster Vaccine
| Status | Active |
|---|---|
| Effective start/end date | 12/7/23 → 12/31/33 |
Funding
- GRITSTONE BIO, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.